Oric Pharmaceuticals Presents Phase 1b Results for NSCLC Drug

Oric Pharmaceuticals reported updated Phase 1b information for enozertinib in previously untreated patients with advanced non-small cell lung cancer carrying atypical EGFR mutations. The results, presented at the European Society for Medical Oncology meeting, showed an 88% best overall response rate and a 80% confirmed response rate by blinded independent central review. Furthermore, all 22 evaluable patients achieved at least a 90% reduction in EGFR-mutant circulating tumor DNA.

The presentation of positive clinical outcomes for enozertinib in a difficult-to-treat cancer population provides insight into the potential commercial viability of the drug. These results may influence market expectations for pharmaceutical products targeting advanced non-small cell lung cancer.